Livforsakringsbolaget Skandia Omsesidigt Buys Shares of 2,515 Stryker Corporation $SYK

Livforsakringsbolaget Skandia Omsesidigt bought a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,515 shares of the medical technology company’s stock, valued at approximately $794,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Varma Mutual Pension Insurance Co increased its holdings in Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares in the last quarter. Swedbank AB boosted its position in shares of Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after buying an additional 7,934 shares during the period. Crossmark Global Holdings Inc. boosted its position in shares of Stryker by 31.1% during the fourth quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after buying an additional 6,367 shares during the period. Finally, Royal Bank of Canada grew its holdings in shares of Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after buying an additional 199,863 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. BTIG Research decreased their price target on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Raymond James Financial set a $370.00 price objective on shares of Stryker in a report on Friday, July 31st. JPMorgan Chase & Co. cut their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, BMO Capital Markets initiated coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Performance

Shares of SYK opened at $331.32 on Friday. The company has a market cap of $127.08 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm has a 50-day moving average of $329.10 and a 200-day moving average of $331.47. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the firm earned $3.13 EPS. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.